TY - JOUR
T1 - Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes
T2 - Cost effectiveness analysis
AU - Gillett, M.
AU - Dallosso, H. M.
AU - Dixon, S.
AU - Brennan, A.
AU - Carey, M. E.
AU - Campbell, M. J.
AU - Heller, S.
AU - Khunti, K.
AU - Skinner, T. C.
AU - Davies, M. J.
PY - 2010/8/26
Y1 - 2010/8/26
N2 - Objectives: To assess the long term clinical and cost effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) intervention compared with usual care in people with newly diagnosed type 2 diabetes. Design: We undertook a cost-utility analysis that used data from a 12 month, multicentre, cluster randomised controlled trial and, using the Sheffield type 2 diabetes model, modelled long term outcomes in terms of use of therapies, incidence of complications, mortality, and associated effect on costs and health related quality of life. A further cost-utility analysis was also conducted using current "real world" costs of delivering the intervention estimated for a hypothetical primary care trust. Setting: Primary care trusts in the United Kingdom. Participants: Patients with newly diagnosed type 2 diabetes. Intervention: A six hour structured group education programme delivered in the community by two professional healthcare educators. Main outcome measures: Incremental costs and quality adjusted life years (QALYs) gained. Results: On the basis of the data in the trial, the estimated mean incremental lifetime cost per person receiving the DESMOND intervention is £209 (95% confidence interval -£704 to £1137; €251, -€844 to €1363; $326, -$1098 to $1773), the incremental gain in QALYs per person is 0.0392 (-0.0813 to 0.1786), and the mean incremental cost per QALY is £5387. Using "real world" intervention costs, the lifetime incremental cost of the DESMOND intervention is £82 (-£831 to £1010) and the mean incremental cost per QALY gained is £2092. A probabilistic sensitivity analysis indicated that the likelihood that the DESMOND programme is cost effective at a threshold of £20 000 per QALY is 66% using trial based intervention costs and 70% using "real world" costs. Results from a one way sensitivity analysis suggest that the DESMOND intervention is cost effective even under more modest assumptions that include the effects of the intervention being lost after one year. Conclusion: Our results suggest that the DESMOND intervention is likely to be cost effective compared with usual care, especially with respect to the real world cost of the intervention to primary care trusts, with reductions in weight and smoking being the main benefits delivered.
AB - Objectives: To assess the long term clinical and cost effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) intervention compared with usual care in people with newly diagnosed type 2 diabetes. Design: We undertook a cost-utility analysis that used data from a 12 month, multicentre, cluster randomised controlled trial and, using the Sheffield type 2 diabetes model, modelled long term outcomes in terms of use of therapies, incidence of complications, mortality, and associated effect on costs and health related quality of life. A further cost-utility analysis was also conducted using current "real world" costs of delivering the intervention estimated for a hypothetical primary care trust. Setting: Primary care trusts in the United Kingdom. Participants: Patients with newly diagnosed type 2 diabetes. Intervention: A six hour structured group education programme delivered in the community by two professional healthcare educators. Main outcome measures: Incremental costs and quality adjusted life years (QALYs) gained. Results: On the basis of the data in the trial, the estimated mean incremental lifetime cost per person receiving the DESMOND intervention is £209 (95% confidence interval -£704 to £1137; €251, -€844 to €1363; $326, -$1098 to $1773), the incremental gain in QALYs per person is 0.0392 (-0.0813 to 0.1786), and the mean incremental cost per QALY is £5387. Using "real world" intervention costs, the lifetime incremental cost of the DESMOND intervention is £82 (-£831 to £1010) and the mean incremental cost per QALY gained is £2092. A probabilistic sensitivity analysis indicated that the likelihood that the DESMOND programme is cost effective at a threshold of £20 000 per QALY is 66% using trial based intervention costs and 70% using "real world" costs. Results from a one way sensitivity analysis suggest that the DESMOND intervention is cost effective even under more modest assumptions that include the effects of the intervention being lost after one year. Conclusion: Our results suggest that the DESMOND intervention is likely to be cost effective compared with usual care, especially with respect to the real world cost of the intervention to primary care trusts, with reductions in weight and smoking being the main benefits delivered.
UR - http://www.scopus.com/inward/record.url?scp=84859005073&partnerID=8YFLogxK
U2 - 10.1136/bmj.c4093
DO - 10.1136/bmj.c4093
M3 - Journal article
C2 - 20729270
AN - SCOPUS:84859005073
SN - 0959-8146
VL - 341
JO - BMJ
JF - BMJ
IS - 7770
M1 - c4093
ER -
